Compare Johnson & Johnson (JNJ) vs Kohl's Corporation (KSS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Kohl's Corporation — how do they compare? Johnson & Johnson trades at $261.54 (market cap $618.09B), while Kohl's Corporation trades at $20.36 (market cap $2.28B). The key difference: Johnson & Johnson is far larger — about 271.1× Kohl's Corporation's market cap, and Kohl's Corporation pays the higher dividend (2.49%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Kohl's Corporation for 48 Days on average.
| JNJ | KSS | |
|---|---|---|
Market Cap | $618.09B | $2.28B |
Volume | 6,050,983 | 4,960,280 |
Sector | Health | Consumer Cyclical |
52-Week High | $278.43 | $24.71 |
52-Week Low | $186.00 | $11.72 |
Typical Hold Time | 129 Days | 48 Days |
Enterprise Value | $646.37B | $7.88B |
Dividend Yield | 2.09% | 2.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
Kohl's (KSS) trades at $20.35, up 1.14% with a bullish technical outlook despite recent earnings beats. The stock shows attractive valuation metrics with P/E of 8.63 and P/S of 0.15, though revenue has declined from $19.4B in 2022 to $16.2B in 2025. Recent Q2 2026 earnings beat expectations with $1.28 EPS versus $0.58 expected, and the company raised full-year guidance amid merchandising improvements.
KSS presents a value opportunity with strong fundamentals but faces headwinds from 18 consecutive quarters of declining sales. Analyst consensus is mixed with 30% buy ratings and a $15.50 price target below current levels. The turnaround story depends on holiday execution and sales stabilization to sustain recent gains beyond tariff-related benefits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →
